Siemens Healthineers Balances Radiotherapy Breakthroughs With Diagnostic Alliances as Analysts Eye 50-Euro Target

Siemens Healthineers pushes Accela radiotherapy and diagnostics partnerships as JPMorgan and Jefferies set price targets above the EUR 37.92 close.

Siemens Healthineers is pressing ahead on two fronts at once — reinventing how cancer patients receive radiation treatment while widening its reach in laboratory diagnostics through outside partnerships. The dual strategy has not gone unnoticed on the analyst circuit, where price targets now sit well above the stock's current trading level.

Shares of the medical technology group finished Friday's session at EUR 37.92, up 1.1 percent on the day. That modest advance masks a rougher stretch: since the turn of the year, the equity has shed 16 percent of its value.

A Radiotherapy Platform Built for Speed

At the heart of the company's product offensive is Accela, a radiation therapy platform built on NeoArc technology. According to Siemens Healthineers, the system can deliver stereotactic irradiation within a single breath-hold cycle and complete multi-target SBRT treatments in just 60 seconds.

That compression of treatment timelines caught the attention of JPMorgan Chase & Co., which on September 29 assigned an "Overweight" rating to the stock. Analyst David Adlington pointed to the efficiency gains that the faster throughput could unlock for medical facilities running radio-oncology programs.

Media reports indicate that Jefferies followed on September 30 with a valuation carrying a EUR 50.00 price target. The bullish calls continued into the following week: on Wednesday, Jefferies reiterated its "Buy" recommendation with the same EUR 50 target, while JPMorgan had already reaffirmed its "Overweight" stance on Tuesday with a price target of EUR 57.40.

Both institutions see meaningful recovery potential, viewing the company as well placed to capitalize on product momentum and the broader digitization of healthcare.

Diagnostics Expansion and Strategic Alliances

Beyond radiation oncology, Siemens Healthineers has been busy broadening its diagnostic footprint. On September 29, the company announced the global rollout of its Innovance D-Dimer 2.0 assay, a diagnostic test that holds both CE marking and 510(k) clearance from the U.S. Food and Drug Administration.

The following day — Thursday — brought news of a strategic collaboration with Truvian Health aimed at advancing the Truvian TruVerus diagnostic system. Under the arrangement, Siemens Healthineers supplies development support, technical resources, manufacturing know-how and commercial advisory services. The two partners also intend to explore joint development and marketing of future diagnostic solutions.

September's activity extended well past diagnostics. On September 21, the company disclosed a partnership with Novo targeting improved care for the liver conditions MASLD and MASH. Earlier in the month, on September 8, it integrated the Vuze guidance software for spinal surgery into its mobile C-arm system Cios Spin. Roughly three weeks ago, Siemens Healthineers also announced an expansion of its medical technology manufacturing capacity — a move that has coincided with a 0.8 percent decline in the share price since.

Cybersecurity Project Adds Another Layer

Media reports describe a separate three-year initiative dubbed SHIELD, focused on cybersecurity for medical devices. The project draws on artificial intelligence and virtual hospital models to plan security updates — an effort that underscores how connected devices in clinical settings demand dependable safeguards against disruptions to patient care.

What Investors Are Watching Next

Attention now turns to the company's upcoming financial reporting. Siemens Healthineers has scheduled its next earnings press conference for November 5, 2026, when it will publish detailed results for the fourth quarter and the full 2026 fiscal year. Management emphasized during a prior pre-close outlook call that reliable actual figures will only be available once the official quarterly close is complete.

At that November briefing, the integration of the new product lines and the progress of ongoing initiatives are likely to take center stage.